wound repair product shown effective

Calzada’s wound repair product shown effective in human trials

Monday, October 15, 2012 by Angela Kean
Calzada’s wound repair product shown effective in human trials

Calzada (ASX: CZD) has achieved a milestone in human clinical trials of its NovoSorb™ wound repair product, which has been implanted and successfully integrated into a wound and closed with skin grafts in two patients.

The first Biodegradable Temporising Matrix (BTM) clinical trial is underway at the Royal Adelaide Hospital.

The trial indicates that the NovoSorb™ BTM wound repair device is performing as expected in a full thickness wound model.

The BTM is well tolerated by human tissues, provides a scaffold into which host tissue can grow, inhibits wound contraction, and once fully integrated provides a bed suitable for graft take.

NovoSkin, a joint venture between Calzada’s wholly owned subsidiary PolyNovo and Associate Professor John Greenwood, is developing a two stage treatment for full thickness burns comprising a Biodegradable Temporising Matrix and Composite Cultured Skin.

The ultimate goal is to abolish the need for skin grafts and improve the quality of the resulting tissue and the speed of the return to function.

NovoSkin is now in the process of completing the current clinical trial work with further recruitment and treatment of patients underway.

These positive early observations should enable the clinical team to broaden patient recruitment into other free flap donor sites or different wound applications, including burns.


BARDA contract application

Following the American Burn Association conference earlier this year, NovoSkin was invited to submit a proposal for a Biomedical Advanced Research and Development Authority contract to further develop its NovoSorb™ products for application as a medical countermeasure in response to mass burn casualties.

The value of the contract is US$16.9 million, which, if received, would be applied to the further development and regulatory approval of BTM in the U.S.

http://www.proactiveinvestors.com.au/companies/news/34509/calzadas-wound-repair-product-shown-effective-in-human-trials-34509.html